Recent studies have reported that the activation of TLR4 is involved in several cardiovascular diseases, and RP105 is a known inhibitor of the TLR4 signalling pathway16, 19 that also plays an essential role in cardiovascular diseases. Here, TLR4 is linked to cardiovascular disorder.